biologic

Clevecord

HPC, Cord Blood

Loss of exclusivitySeptember 2028projected — 12-year biologic exclusivity estimate
CompanyCleveland Cord Blood Center

Drug detail

Brand nameClevecord
Active ingredientHPC, Cord Blood
Strength5 x 10^8 TOTAL NUCLEATED CELLS WITH AT LEAST 1.25 x 106 VIABLE CD34+ CELLS
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalSeptember 2016
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Clevecord patent cliff — loss of exclusivity September 2028 | CliffBio